How common is contrast nephropathy in the general outpatient setting? When you send one of your outpatients to get a CT scan with iv contrast, what is the real risk? Much of the randomized, controlled trial data on…
As much as kidney transplant outcomes have improved over the decades, we’re not perfect: a sizable group of patients end up transitioning to dialysis therapies after the kidney transplant stops working. What should be done with the allograft…
Warfarin has recently been associated with an increased risk of stroke in ESRD patients with atrial fibrillation. This makes the decision whether to initiate warfarin therapy in dialysis patients with atrial fibrilltion anything but clear cut. Add to…
Last week’s poll results: who should provide funding for large, randomized controlled drug trials? Most respondents (58%) chose the diplomatic answer and said that it should be a combination between government and pharmaceutical companies. I was somewhat surprised…
I was on the phone to one of my friends the other day. He’s a renal fellow currently doing lab-based research in Boston. He’s been having a difficult time of it lately, with none of his experiments working…
Peter Mundel, a well-known researcher of podocyte biology, gave our Renal Grand Rounds today. Here’s what I took away from this morning’s talk: -regulation of the podocyte’s actin cytoskeleton is postulated to be the final common pathway in…
You may have come across the phrase “Luminex beads” while doing your transplant nephrology rotation, or heard the term while hanging out in the Tissue Typing Lab. This post is intended to briefly describe the Luminex technology and…
This month’s Kidney International “Nephrology Image” features a report by Chen et al in which they describe a PD patient who noted cloudy, deep green dialysate fluid upon drainage of their peritoneum. They also presented with right upper…
This month’s issue of AJKD includes an enlightening group of 6 editorials, each written from a unique perspective (e.g., the perspective of large dialysis corporations, the perspective of the ESRD Networks, the perspective of non-profit dialysis corporations, etc.),…
Linking up nicely with Nate’s rituximab post from this Tuesday, I wanted to mention a patient with lupus nephritis whom I saw in clinic this week. She had had horrendous renal disease, as seen on the three kidney…